Argireline vs Palmitoyl Pentapeptide-4
A side-by-side research comparison of Argireline and Palmitoyl Pentapeptide-4 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | Palmitoyl Pentapeptide-4 |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | Palmitoyl Pentapeptide-4 (Matrixyl Original) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | Mimics collagen breakdown products (matrikines) that signal fibroblasts to produce new collagen matrix components including types I, III, and IV collagen. |
| Molecular weight | 889 Da | 802.05 Da |
| Half-life | 8-12 hours (topical) | N/A (topical depot effect) |
| Bioavailability | Moderate (topical) | Topical: ~8-12% penetration |
| Typical dose | 5-10% solution | 2-8% in formulation |
| Frequency | 2x daily | 2x daily |
| Route | Topical | Topical serum or cream |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
Palmitoyl Pentapeptide-4 reported benefits
- Proven collagen stimulation
- Wrinkle depth reduction
- Improved skin firmness
- Well-tolerated
Related comparisons
Research and educational reference only. Not medical advice.